New Entrant In Diabetes Market

BMI is restating the attractiveness of the Middle East region to pharmaceutical and biotechnology companies involved in the diabetes field after US-based Generex Biotechnology signed a licensing deal for its revolutionary insulin product. With many countries in the region demonstrating the highest prevalence of the disease in the world, this scenario should continue for some time. Indeed, after gaining first approval in the US or Western Europe, we strongly recommend producers of insulin products and diabetes diagnostics to introduce their offerings to the Middle Eastern markets immediately afterwards, given the inevitable swift uptake.

To read the full article, please choose one of the following options: